Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | RAF1 | P04049 | 4/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | EPHA1 | P21709 | 3/20 | 0.48 |
| ▸ | TTK | P33981 | 3/20 | 0.48 |
| ▸ | FLT4 | P35916 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | CLK1 | P49759 | 3/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.48 |
| ▸ | CDK17 | Q00537 | 3/20 | 0.48 |
| ▸ | TEK | Q02763 | 3/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239293 | 0.98 | ABL1 (0.49) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2241236 | 0.93 | MAPK14 (0.48) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2243874 | 0.93 | ABL1 (0.58) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2242892 | 0.92 | MAPK14 (0.48) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2243155 | 0.92 | MAPK14 (0.46) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2240921 | 0.91 | ABL1 (0.58) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2241466 | 0.90 | KCNJ6 (0.47) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2240648 | 0.89 | MAPK14 (0.58) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2247857 | 0.89 | MAPK14 (0.49) | ABL1MAPK14BRAFRAF1RET | |
| SCHEMBL2243747 | 0.89 | ABL1 (0.58) | ABL1MAPK14BRAFRAF1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | claimed |
| EP-2044053-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | Bayer Healthcare, LLC (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2007064872-A2 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | claimed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195110-A1 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER | UMPS, SLC14A1, CPS1 | ABL1 3359/4885MAPK14 3645/4885BRAF 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.